PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-25.41%
Negative EBIT growth while AGEN is at 6.39%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
-25.41%
Negative operating income growth while AGEN is at 6.38%. Joel Greenblatt would press for urgent turnaround measures.
610.74%
Net income growth above 1.5x AGEN's 3.47%. David Dodd would check if a unique moat or cost structure secures superior bottom-line gains.
609.26%
EPS growth above 1.5x AGEN's 6.25%. David Dodd would review if superior product economics or effective buybacks drive the outperformance.
609.26%
Diluted EPS growth above 1.5x AGEN's 6.25%. David Dodd would see if there's a robust moat protecting these shareholder gains.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
320.27%
OCF growth above 1.5x AGEN's 13.33%. David Dodd would confirm a clear edge in underlying cash generation.
320.27%
FCF growth above 1.5x AGEN's 13.99%. David Dodd would verify if the firm’s strategic investments yield superior returns.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
419.54%
10Y OCF/share CAGR above 1.5x AGEN's 86.63%. David Dodd would check if a superior product mix or cost edge drives this outperformance.
419.54%
5Y OCF/share CAGR above 1.5x AGEN's 85.65%. David Dodd would confirm if the firm has better cost structures or brand premium boosting mid-term cash flow.
400.10%
3Y OCF/share CAGR above 1.5x AGEN's 65.66%. David Dodd would confirm if the firm is quickly gaining an operational edge over the competitor.
706.07%
Net income/share CAGR above 1.5x AGEN's 83.57% over 10 years. David Dodd would confirm if brand, IP, or scale secure this persistent advantage.
706.07%
5Y net income/share CAGR above 1.5x AGEN's 83.57%. David Dodd would confirm if the firm’s strategy is more effective in generating mid-term profits.
315.93%
3Y net income/share CAGR above 1.5x AGEN's 72.72%. David Dodd would confirm the company’s short-term strategies outmatch the competitor significantly.
-251.89%
Both are negative. Martin Whitman suspects the segment is in decline or saddled with persistent unprofitability or write-downs.
-251.89%
Both show negative equity/share growth mid-term. Martin Whitman suspects cyclical or structural challenges for each company.
-24.04%
Negative 3Y equity/share growth while AGEN is at 51.25%. Joel Greenblatt demands an urgent fix in capital structure or profitability vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
20.74%
Positive BV/share change while AGEN is negative. John Neff sees a clear edge over a competitor losing equity.
-14.44%
We’re deleveraging while AGEN stands at 6.01%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
No Data
No Data available this quarter, please select a different quarter.
30.71%
We expand SG&A while AGEN cuts. John Neff might see the competitor as more cost-optimized unless we expect big payoffs from the overhead growth.